What is the Bifidobacterium infantis 35624 strain?
Bifidobacterium infantis 35624, also commercially known as Bifantis® and often referred to by its updated name Bifidobacterium longum subsp. longum 35624, is a specific, well-researched probiotic strain. It was originally isolated from the gastrointestinal tract of a healthy human. Its name reflects a taxonomic reclassification, but the original designation is still widely used in commercial products and research to identify this particular strain.
The specificity of this strain is crucial, as the health effects of probiotics are highly strain-specific. A benefit observed in one strain of Bifidobacterium cannot be assumed for another, even if they belong to the same species. The unique characteristics of B. infantis 35624 allow it to survive stomach acid, adhere to the intestinal lining, and effectively interact with the gut microbiome.
How does Bifidobacterium infantis 35624 work?
Unlike many probiotics that simply add 'good' bacteria, B. infantis 35624 has a more nuanced mechanism of action. Its primary functions involve modulating the host's immune response and interacting metabolically with the gut environment.
Key mechanisms of action include:
- Immunomodulation: The strain helps to regulate the immune system by promoting anti-inflammatory responses. Clinical studies have shown it can reduce pro-inflammatory biomarkers like C-reactive protein (CRP), TNF-α, and IL-6 in patients with inflammatory conditions. In healthy individuals, it can also reduce inflammatory responses to stimuli.
- Intestinal Barrier Support: B. infantis 35624 enhances the integrity of the gut barrier, a crucial defense against harmful substances. In preclinical studies, it has been shown to protect against intestinal permeability and damage caused by infections.
- Production of Short-Chain Fatty Acids (SCFAs): Like other bifidobacteria, this strain ferments dietary fibers to produce SCFAs, such as acetate. Acetate helps lower the gut's pH, creating an environment less favorable for pathogens and nourishing the cells lining the intestine.
- Competition Against Pathogens: By effectively competing for resources and adhesion sites, B. infantis 35624 helps crowd out and inhibit the growth of harmful microorganisms in the gut.
Key benefits and uses
The most well-documented benefit of Bifidobacterium infantis 35624 is its efficacy in managing symptoms of Irritable Bowel Syndrome (IBS). Clinical trials have demonstrated significant symptom relief, particularly for women with IBS.
Specific benefits for IBS sufferers include:
- Reduced abdominal pain and discomfort: Numerous studies have shown a significant decrease in the severity and frequency of abdominal pain.
- Relief from bloating and gas: The probiotic helps reduce symptoms of bloating and distention, common complaints among IBS patients.
- Improved bowel habit satisfaction: This strain has been shown to improve overall satisfaction with bowel habits.
- Enhanced quality of life: By alleviating core IBS symptoms, the strain also contributes to a clinically meaningful improvement in the quality of life for patients.
Other potential benefits:
- Anti-inflammatory effects: Research suggests the strain's immunomodulatory properties may help with conditions beyond the gut, such as chronic fatigue syndrome and psoriasis, by reducing systemic inflammation.
- Pediatric IBS management: A 2024 study provided real-world evidence of its effectiveness in reducing IBS symptoms and improving quality of life in children and adolescents.
Bifidobacterium infantis 35624 vs. other probiotic strains
It's important to understand the concept of strain specificity when comparing different probiotics. Not all strains, even within the same species, have the same effects. This is highlighted in the comparison below.
| Feature | Bifidobacterium infantis 35624 | Other Probiotic Strains (e.g., L. rhamnosus GG) |
|---|---|---|
| Primary Indication | Most evidence is for Irritable Bowel Syndrome (IBS) symptom relief. | Broader applications, including diarrhea prevention, general immune support, etc.. |
| Main Mechanism | Immunomodulation (e.g., reduces pro-inflammatory markers) and gut barrier support. | Mechanisms vary widely. Some focus on competitive exclusion of pathogens, lactic acid production, or other immune effects. |
| Clinical Efficacy | Strong evidence for reducing IBS-related abdominal pain, bloating, and discomfort. | Varies widely by strain and condition. Effects on IBS may be less pronounced or require a different dosage/formulation. |
| Formulation Specificity | Effective doses and delivery mechanisms are crucial for efficacy; studies have shown dose-dependent effects and influences of the matrix (e.g., malted milk vs. capsule). | Tolerable and effective doses vary. Dosage and formulation are critical for achieving targeted benefits. |
| Commercial Example | The single strain in Align® probiotics. | Found in various products, including yogurts and multi-strain supplements. |
Clinical studies and evidence
Extensive research, including randomized controlled trials and observational studies, supports the use of B. infantis 35624.
- IBS studies: A major 2006 double-blind, placebo-controlled trial found that a specific dose of B. infantis 35624 significantly improved abdominal pain, bloating, and composite symptom scores in women with IBS. Another real-world observational study from 2022 corroborated these findings, showing reduced IBS severity and improved quality of life over 30 days.
- Anti-inflammatory research: Studies involving patients with ulcerative colitis, chronic fatigue syndrome, and psoriasis showed that supplementation reduced plasma levels of inflammatory biomarkers compared to placebo.
- Pediatric population: A recent 2024 study investigated the effects in children and adolescents with IBS, reporting significant symptom reduction and a shift towards less severe IBS categories.
- Formulation matters: A meta-analysis published in 2017 noted that while some studies on single-strain B. infantis 35624 showed inconsistent results, composite probiotics containing the strain demonstrated significant alleviation of bloating and pain. The takeaway is that the delivery method and overall formulation play a role in effectiveness.
Side effects and safety
Bifidobacterium infantis 35624 is generally considered safe and well-tolerated for most people. Clinical studies typically report mild and temporary side effects, with no significant difference in adverse events compared to a placebo.
Reported side effects are generally confined to the digestive system and may include:
- Mild gas or bloating, especially during the first few weeks as the gut adjusts.
- Stomach discomfort.
It is important to note that individuals with compromised immune systems or those with serious underlying medical conditions should consult a healthcare provider before starting any probiotic. The probiotic may also be less effective if taken with certain antibiotics.
How to choose a supplement with Bifidobacterium infantis 35624
When selecting a probiotic containing B. infantis 35624, several factors are important to consider:
- Check the strain: Ensure the product specifically lists Bifidobacterium infantis 35624 (or its updated name, B. longum subsp. longum 35624) on the label. As mentioned, benefits are strain-specific.
- Verify the CFU count: For IBS, clinical studies have used doses of around 1 x 10⁸ CFU (100 million CFU). However, some studies have shown variable results, emphasizing the need for robust clinical data for the specific dose and form. Follow the dosage instructions provided by the manufacturer.
- Reputable brand: Choose brands like Align® that have been clinically tested and ensure the bacteria remain viable until the 'best by' date.
- No refrigeration required: The strain used in some products like Align is freeze-dried and shelf-stable, making it convenient for daily use.
Conclusion
Bifidobacterium infantis 35624 is a unique and clinically validated probiotic strain with a strong track record for alleviating symptoms of Irritable Bowel Syndrome. Its mechanism of action, which involves modulating gut inflammation, fortifying the intestinal barrier, and producing beneficial compounds, sets it apart from many other probiotics. Supported by robust clinical evidence in both adults and pediatric patients, this strain offers a targeted approach to managing digestive discomfort. When choosing a supplement, paying close attention to the specific strain and dosage, as well as considering advice from healthcare professionals, is key to maximizing its potential benefits.
For more detailed research, refer to the study: A Novel Probiotic for the Treatment of Irritable Bowel Syndrome.
